Craig Tooman
Chief Executive Officer bei SILENCE THERAPEUTICS PLC
Vermögen: 78 964 $ am 31.03.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ingmar Hoerr | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 21 Jahre |
Carolyn Cross | F | 62 | 28 Jahre | |
Florian von der Muelbe | M | 52 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 24 Jahre |
Jean Charest | M | 65 | 6 Jahre | |
Michael Brosnan | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 Jahre |
Nicolas Loebel | M | 64 | 20 Jahre | |
Tom Dawson | M | - | - | |
Baron Jean Stéphenne | M | 73 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 Jahre |
Simon Sinclair | M | 52 | 3 Jahre | |
Ulrike Gnad-Vogt | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 13 Jahre |
Rhonda L. Hellums | F | 52 | 8 Jahre | |
Steven Romano | M | 64 | 5 Jahre | |
Friedrich von Bohlen und Halbach | M | 60 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Gem Hopkins | M | - | 4 Jahre | |
Marie Wikström Lindholm | M | - | 7 Jahre | |
Igor Splawski | M | 56 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 4 Jahre |
Debra Stephanie Barker | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 Jahre |
Bernd Winterhalter | M | 65 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 Jahre |
Roger Andersen | M | - | - | |
Angelika Vance | F | - | - | |
Timothy M. Wright | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 6 Jahre |
Sarah Fakih | M | - | - | |
Mariola Fotin-Mleczek | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 18 Jahre |
David Lemus | M | 61 | 6 Jahre | |
Mathias Hothum | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 Jahre |
Junaid Bajwa | M | 45 | 3 Jahre | |
Ralf Clemens | M | 71 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 Jahre |
Mike Farrar | M | 64 | 3 Jahre | |
Jean Duvall | F | 63 | 3 Jahre | |
Hans Tanner | M | 72 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 Jahre |
Pierre Kemula | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 8 Jahre |
Jason Hickok | M | - | - | |
J.P. Gabriel | M | - | 1 Jahre | |
Patrick Baumhof | M | - | - | |
Klaus Schollmeier | M | 67 | 2 Jahre | |
Bettina Jödicke-Braas | F | - | - | |
Bill Kanz | M | - | - | |
Myriam Mendila | M | 58 | 1 Jahre | |
Iain Ross | M | 71 | 5 Jahre | |
Viola Bronsema | M | 61 | 4 Jahre | |
Nikita Parkhaev | F | - | - | |
James Ede-Golightly | M | 44 | 5 Jahre | |
Malte Greune | M | 59 | 3 Jahre | |
Antony Blanc | M | 57 | 4 Jahre | |
Eric Fink | M | - | 2 Jahre | |
Jean Stephenne | M | 75 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Michael Davidson | M | 67 | 3 Jahre | |
Linnea Corwin Elrington | F | - | 7 Jahre | |
Alexander Zehnder | M | 54 | 1 Jahre | |
Eric Floyd | M | 62 | 5 Jahre | |
Curtis Rambaran | M | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Andrew D. Rackear | M | 70 | 11 Jahre | |
Mark Rothera | M | 62 | 2 Jahre | |
Jeffrey H. Buchalter | M | 67 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 9 Jahre |
Kenneth Zuerblis | M | 64 | 14 Jahre | |
Richard L. Love | M | 81 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 10 Jahre |
Robert O’Holla | M | 72 | 7 Jahre | |
Thomas F. Deuel | M | 89 | 3 Jahre | |
Richard Young | M | 70 | 3 Jahre | |
Evan S. Melrose | M | 54 | 3 Jahre | |
Alistair Gray | M | 75 | 9 Jahre | |
Alexander Denner | M | 54 | 4 Jahre | |
Giles Campion | M | 69 | 4 Jahre | |
Bob C. Salisbury | M | 80 | 8 Jahre | |
Timothy Patrick Lynch | M | 54 | 3 Jahre | |
Brian Levy | M | 72 | 4 Jahre | |
Robert Quinn | M | 41 | 4 Jahre | |
Tim McInerney | M | 63 | 7 Jahre | |
Anthony J. Yost | M | 65 | 7 Jahre | |
Aby Buchbinder | M | 55 | 7 Jahre | |
Lee M. Greenberger | M | - | - | |
Klaus Edvardsen | M | 62 | 1 Jahre | |
Javesh Shah | M | - | - | |
Sunil Mehta | M | 65 | - | |
Shauna M. Tholen | F | - | 1 Jahre | |
Larry Miller | M | - | 1 Jahre | |
John Strafford | M | - | 5 Jahre | |
John D. Weinberg | M | 57 | 2 Jahre | |
Jorgen Wittendorff | M | - | 4 Jahre | |
Kalyanasundaram Sundaram | M | 70 | - | |
Dimitris Voliotis | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 Jahre |
Joseph Errico | M | 55 | - | |
Richard Mulligan | M | 69 | 4 Jahre | |
Franz-Werner Haas | M | 54 | 11 Jahre | |
Joy Amundson | F | 69 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 2 Jahre |
Bruce Williams | M | 69 | 2 Jahre | |
Ulrich Grau | M | 75 | 3 Jahre | |
Mark P. Mellin | M | 62 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 4 Jahre |
Victor Micati | M | 83 | 6 Jahre | |
Martin D. Meglasson | M | 74 | 4 Jahre | |
Eric J. Liebler | M | 60 | 3 Jahre | |
Gregory Weaver | M | 68 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 3 Jahre |
Jack Geltosky | M | 78 | 1 Jahre | |
Ivan D. Horak | M | 73 | 6 Jahre | |
Phillip M. Renfro | M | 78 | 5 Jahre | |
Göran Albert Ando | M | 75 | - | |
Rosina B. Dixon | M | 81 | 12 Jahre | |
Corey Levenson | M | 69 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 8 Jahre |
Daniel L. Menichella | M | 64 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 Jahre |
Mike Long | M | - | 1 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 38 | 38,00% |
Deutschland | 29 | 29,00% |
Vereinigtes Königreich | 19 | 19,00% |
Kanada | 15 | 15,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Craig Tooman
- Persönliches Netzwerk